KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Aquestive Therapeutics (AQST) FCF Margin (2017 - 2025)

Historic FCF Margin for Aquestive Therapeutics (AQST) over the last 9 years, with Q3 2025 value amounting to 100.6%.

  • Aquestive Therapeutics' FCF Margin fell 122800.0% to 100.6% in Q3 2025 from the same period last year, while for Sep 2025 it was 387.23%, marking a year-over-year increase of 4455900.0%. This contributed to the annual value of 3563.29% for FY2024, which is 35487100.0% down from last year.
  • Latest data reveals that Aquestive Therapeutics reported FCF Margin of 100.6% as of Q3 2025, which was down 122800.0% from 80.19% recorded in Q2 2025.
  • In the past 5 years, Aquestive Therapeutics' FCF Margin ranged from a high of 79.16% in Q1 2023 and a low of 269.9% during Q1 2025
  • In the last 5 years, Aquestive Therapeutics' FCF Margin had a median value of 77.58% in 2021 and averaged 64.16%.
  • Per our database at Business Quant, Aquestive Therapeutics' FCF Margin soared by 19243000bps in 2021 and then plummeted by -1835000bps in 2025.
  • Quarter analysis of 5 years shows Aquestive Therapeutics' FCF Margin stood at 77.58% in 2021, then soared by 201bps to 78.54% in 2022, then plummeted by -148bps to 37.54% in 2023, then surged by 139bps to 14.55% in 2024, then tumbled by -791bps to 100.6% in 2025.
  • Its FCF Margin was 100.6% in Q3 2025, compared to 80.19% in Q2 2025 and 269.9% in Q1 2025.